Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Shares Purchased by Alliancebernstein L.P.

Alliancebernstein L.P. raised its stake in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 1.2% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 61,500 shares of the biopharmaceutical company’s stock after buying an additional 708 shares during the quarter. Alliancebernstein L.P.’s holdings in Agios Pharmaceuticals were worth $2,021,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Venturi Wealth Management LLC purchased a new stake in shares of Agios Pharmaceuticals in the fourth quarter valued at $33,000. Franklin Resources Inc. purchased a new position in Agios Pharmaceuticals in the 3rd quarter valued at about $1,499,000. Vanguard Group Inc. boosted its stake in shares of Agios Pharmaceuticals by 1.5% during the 4th quarter. Vanguard Group Inc. now owns 5,631,321 shares of the biopharmaceutical company’s stock worth $185,045,000 after purchasing an additional 85,339 shares during the last quarter. Bank of New York Mellon Corp grew its holdings in shares of Agios Pharmaceuticals by 48.8% during the fourth quarter. Bank of New York Mellon Corp now owns 265,514 shares of the biopharmaceutical company’s stock worth $8,725,000 after buying an additional 87,089 shares in the last quarter. Finally, Norges Bank purchased a new position in shares of Agios Pharmaceuticals during the fourth quarter valued at approximately $4,768,000.

Agios Pharmaceuticals Trading Down 2.4 %

Shares of AGIO opened at $27.14 on Thursday. Agios Pharmaceuticals, Inc. has a twelve month low of $23.42 and a twelve month high of $62.58. The firm has a market capitalization of $1.56 billion, a P/E ratio of 2.39 and a beta of 0.83. The stock’s fifty day simple moving average is $31.00 and its 200 day simple moving average is $38.90.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported ($1.74) earnings per share for the quarter, missing the consensus estimate of ($1.69) by ($0.05). Agios Pharmaceuticals had a net margin of 1,845.92% and a negative return on equity of 2.51%. Sell-side analysts predict that Agios Pharmaceuticals, Inc. will post -6.85 earnings per share for the current year.

Insider Buying and Selling at Agios Pharmaceuticals

In other news, Director Jacqualyn A. Fouse sold 7,497 shares of the stock in a transaction dated Thursday, April 10th. The stock was sold at an average price of $25.90, for a total value of $194,172.30. Following the completion of the sale, the director now owns 149,220 shares in the company, valued at approximately $3,864,798. This trade represents a 4.78 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 4.93% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several analysts have commented on the stock. HC Wainwright started coverage on shares of Agios Pharmaceuticals in a research note on Monday, February 24th. They issued a “buy” rating and a $58.00 target price for the company. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Agios Pharmaceuticals in a research report on Wednesday, December 18th. Finally, StockNews.com downgraded Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, February 14th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $56.57.

Agios Pharmaceuticals Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.